Observational studyCancer medicine2026
Comparative Outcomes Between Black and White Patients With Early-Stage Diffuse Large B-Cell Lymphoma.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDeterminants of survival in DLBCL stage I-IV collectively have reported Black patients and advanced stage to have worse outcomes on multivariate analysis. As advanced stage is a factor in outcome, available data have not focused on early-stage DLBCL to evaluate the impact of race and SES on outcome. To address this research gap, the study aims to examine and compare the characteristics and the determinants of survival between US Black and White patients with early-stage (I-II) DLBCL.
methodsA retrospective NCDB analysis of early-stage DLBCL patients was conducted, comparing sociodemographic, clinical, and treatment factors between Black and White groups. Chi-square tests assessed differences. Multivariate Cox regression identified survival predictors. Matched patient pairs were analyzed using Cox models with robust variance, and Kaplan-Meier curves evaluated survival outcomes by race.
results81,430 early-stage DLBCL patients diagnosed between 2004 and 2017 included 5,709 Black and 75,721 White patients. Multivariate analysis showed higher mortality risk for males (HR 1.09), aged ≥ 60 (HR 2.04), ≥ 2 comorbidities (HR 1.92), B symptoms (HR 1.23), HIV infection (HR 1.59), and lower income (HR 1.18) (all p < 0.0001). Notably, survival rates between Black and White patients were not significantly different (HR 0.98, p = 0.5263).
conclusionBlack patients have been reported to have worse survival for DLBCL, considering all stages collectively. The remarkable finding of our study was that despite disparities in socioclinical determinants, no overall survival difference was observed between Black and White patients with early-stage DLBCL. We suggest that the similar survival in early-stage DLBCL for Black and White patients is primarily overcome by the favorable remission rate of early-stage DLBCL and accessibility to conventional chemoimmunotherapy. We also imply that the survival disparity between Black and White patients in DLBCL is more likely to be the impact of socioclinical determinants on advanced stage III/IV DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.